Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,049 across all filing types
Latest filing 2022-01-27 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received ANDA approval from the U.S. FDA for certain pharmaceutical products. It is addressed to stock exchanges and includes a request to take the announcement on record. The content is a media release about regulatory approval and product launch, not a financial report, earnings release, or management discussion. The document length is 4171 characters, which is relatively short and primarily an announcement. There is no financial data, no meeting materials, no voting results, no legal proceedings, no capital changes, and no executive changes. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2022-01-27 English
Loss of Share Certificates
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is extremely short (279 characters) and consists mainly of a table listing shareholder names, folio numbers, certificate numbers, and share counts. There is no narrative, financial data, or detailed report content. This resembles a shareholder list or a voting result summary rather than a full report. Given the nature of the data, it is most consistent with a Declaration of Voting Results & Voting Rights Announcements (DVA), which typically includes shareholder names and shareholdings related to voting outcomes. The document does not contain financial statements or management commentary, so it is not an Annual Report or Interim Report. It is not a Regulatory Filing or Report Publication Announcement because it contains actual data rather than just a notice. Therefore, the best classification is DVA with high confidence.
2022-01-21 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a licensing agreement between Glenmark Specialty S.A. and Lotus International Pte. Ltd. for commercialization of a pharmaceutical product (Ryaltris™) in specific markets. It contains no financial statements, regulatory filings, or detailed financial data. It is not an earnings release, annual report, or any form of financial report. It is a corporate announcement about a commercial partnership and licensing deal. Such announcements about business agreements and partnerships fall under the category of Capital/Financing Update (CAP) as they relate to company financing and commercial arrangements. The document is about a licensing agreement with upfront and milestone payments, which is a financing-related update rather than a merger or acquisition filing. Therefore, the appropriate classification is CAP with high confidence.
2022-01-20 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received tentative approval from the U.S. FDA for a specific drug product. It is addressed to stock exchanges and includes a request to take the announcement on record. The content is a media release about a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is about 4050 characters, which is relatively short and consistent with an announcement rather than a detailed report. There is no financial data, no discussion of financial results, no meeting materials, or voting results. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about a significant corporate event that does not fit other categories.
2022-01-17 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Specialty S.A. received FDA approval for a new drug (Ryaltris™ nasal spray). It is addressed to stock exchanges and includes a media release about the approval and marketing plans. There are no financial statements, regulatory certifications, or detailed financial data. The content is a corporate announcement about a product approval, not a financial report or regulatory filing. It is not an earnings release, annual report, or any other financial filing. The document is a corporate press release announcing a significant business development (FDA approval). This type of document fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-01-14 English
Credit Rating
Regulatory Filings Classification · 95% confidence The document is very short (319 characters) and contains a table showing revised and previous credit ratings with remarks. There is no detailed financial data, no mention of a report or filing, and no regulatory or management information. The content is a credit rating update, which does not fit into any specific detailed report category. Given the brevity and nature, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit elsewhere.
2021-12-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.